• 1
    Platz EA,De Marzo AM. Epidemiology of inflammation and prostate cancer. J Urol 2004; 271: S36S40.
  • 2
    Schatteman PH,Hoekz L,Wyndaele JJ,Jeuris W,Van Marck E. Inflammation in prostate biopsies of men without prostatic malignancy or clinical prostatitis: correlation with total serum PSA and PSA density. Eur Urol 2000; 37: 40412.
  • 3
    Gerstenbluth RE,Seftel AD,MacLennan GT,Rao RN,Corty EW,Ferguson K,Resnick MI. Distribution of chronic prostatitis in radical prostatectomy specimens with up-regulation of bcl-2 in areas of inflammation. J Urol 2002; 167: 226770.
  • 4
    Di Silverio F,Gentile V,De Matteis A,Mariotti G,Guiseppe V,Luigi PA,Sciarra A. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol 2003; 43: 16475.
  • 5
    Putzi MJ,De Marzo AM. Morphologic transitions between proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Urology 2000; 56: 82832.
  • 6
    Carpten JD,Nupponen N,Isaacs SD,Sood R,Robbins C,Xu J,Faruque M,Moses T,Ewing CM,Gillanders E,Hu P,Bujnovszky P, et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet 2002; 30: 1814.
  • 7
    Casey G,Neville PJ,Plummer SJ,Xiang Y,Krumroy LM,Klein EA,Catalona WJ,Nupponen N,Carpten JD,Trent JM,Silverman R,Witte JS. RNASEL Arg262Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet 2002; 32: 5813.
  • 8
    Xu J,Zheng SL,Komiya A,Mychaleckyj JC,Isaacs SD,Hu JJ,Sterling D,Lange EM,Hawkins GA,Turner A,Ewing CM,Faith DA, et al. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet 2002; 32: 3215.
  • 9
    Wiklund F,Jonsson B-A,Goransson I,Bergh A,Gronberg H. Linkage analysis of prostate cancer susceptibility: confirmation of linkage at 8p22-23. Hum Genet 2003; 112: 41418.
  • 10
    Xu J,Zheng L,Komiya A,Mychaleckyj JC,Isaacs SD,Chang B,Turner AR,Ewing CM,Wiley KE,Hawkins GA,Bleecker ER,Walsh PC, et al. Common sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Am J Hum Genet 2003; 72: 20812.
  • 11
    Irani J,Goujon J-M,Ragni E,Peyrat L,Hubert J,Saint F,Mottet N, Pathologist Multi Center Study Group. High-grade inflammation in prostate cancer as a prognostic factor for biochemical recurrence after radical prostatectomy. Urology 1999; 54: 46772.
  • 12
    Mohamed-Ali V,Goodrick S,Rawesh A,Katz DR,Miles JM,Yudkin JS,Klein S,Coppack SW. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997; 82: 4196200.
  • 13
    Mohamed-Ali V,Pinkney JH,Coppack SW. Adipose tissue as an endocrine and paracrine organ. Int J Obes Relat Metab Disord 1998; 22: 114558.
  • 14
    Twillie DA,Eisenberger MA,Carducci MA,Hseih W,Kim WY,Simmons JW. Interleukin-6: a candidate mediator of prostate cancer morbidity. Urology 1995; 45: 5429.
  • 15
    Corcoran NM,Costello AJ. Interleukin-6: minor player or starring role in the development of hormone-refractory prostate cancer? BJU Int 2003; 91: 54553.
  • 16
    Adler HL,McCurdy MA,Kattan MW,Timme TL,Scardino PT,Thompson TC. Elevated levels of circulating interleukin-6 and transforming growth factor-β1 in patients with metastatic prostatic carcinoma. J Urol 1999; 161: 1827.
  • 17
    Lehrer S,Diamond EJ,Mamkine B,Droller MJ,Stone NN,Stock RG. C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer. BJU Int 2005; 95: 9612.
  • 18
    Drachenberg DE,Elgamal A-AA,Rowbotham R,Peterson M,Murphy GP. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 1999; 41: 12733.
  • 19
    McArdle PA,McMillan DC,Sattar N,Wallace AM,Underwood MA. The relationship between interleukin-6 and C-reactive protein in patients with benign and malignant prostate disease. Br J Cancer 2004; 91: 17557.
  • 20
    McArdle PA,Mir K,Almushatat ASK,Wallace AM,Underwood MA,McMillan DC. Systematic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer. Urol Int 2006; 77: 1279.
  • 21
    Beer TM,Lalani AS,Lee S,Mori M,Eilers KM,Curd JG,Henner WD,Ryan CW,Venner P,Ruether JD,Chi KN. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial. Cancer 2008; 112: 237783.
  • 22
    Platz EA,De Marzo AM,Erlinger TP,Rifai N,Visvanathan K,Hoffman SC,Helzlsouer KJ. No association between pre-diagnostic plasma c-reactive protein concentration and subsequent prostate cancer. Prostate 2004; 59: 393400.
  • 23
    Il'yasova D,Colbert LH,Harris TB,Newman AB,Bauer DC,Satterfield S,Kritchevsky SB. Circulating levels of inflammatory makers and cancer risk in the Health Aging and Body Composition Cohort. Cancer Epidemiol Biomarkers Prev 2005; 14: 241318.
  • 24
    Siemes C,Visser LE,Coebergh JW,Splinter TA,Witteman JC,Uitterlinden AG,Hofman A,Pols HA,Stricker BH. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol 2006; 24: 521622.
  • 25
    Baillargeon J,Platz EA,Rose DP,Pollock BH,Ankerst DP,Haffner S,Higgins B,Lokshin A,Troyer D,Hernandez J,Lynch S,Leach RJ, et al. Obesity, adipokines, and prostate cancer in a prospective population-based study. Cancer Epidemiol Biomarkers Prev 2006; 15: 13315.
  • 26
    Castell JV,Geiger T,Gross V,Andus T,Walter E,Hirano T,Kishimoto T,Heinrich PC. Plasma clearance, organ distribution and target cells of interleukin-6/hepatocyte-stimulating factor in the rat. Eur J Biochem 1988; 177: 35761.
  • 27
    Fishman D,Faulds G,Jeffery R,Mohamed-Ali V,Yudkin JS,Humphries S,Woo P. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102: 136976.
  • 28
    Margaglione M,Bossone A,Cappucci G,Colaizzo D,Grandone E,Di Minno G. The effect of the interleukin-6 c/g-174 polymorphism and circulating interleukin-6 on fibrinogen plasma levels. Haematologica 2001; 86: 199204.
  • 29
    Jones KG,Brull DJ,Brown LC,Sian M,Greenhalgh RM,Humphries SE,Powell JT. Interleukin-6 (IL-6) and the prognosis of abdominal aortic aneurysms. Circulation 2001; 103: 22605.
  • 30
    Michaud DS,Daugherty SE,Berndt SI,Platz EA,Yeager M,Crawford ED,Hsing A,Huang WY,Hayes RB. Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. Cancer Res 2006; 66: 452530.
  • 31
    Sun J,Hedelin M,Zheng SL,Adami HO,Bensen J,Augustsson-Balter K,Chang B,Adolfsson J,Adams TS,Turner A,Meyers DA,Isaacs WB, et al. Interleukin-6 sequence variants are not associated with prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2004; 13: 16779.
  • 32
    Tan D,Wu X,Hou M,Lee SO,Lou W,Wang J,Janarthan B,Nallapareddy S,Trump DL,Gao AC. Interleukin-6 polymorphism is associated with more aggressive prostate cancer. J Urol 2005; 174: 7536.
  • 33
    Hennekens CH,Buring JE,Manson JE,Stampfer M,Rosner B,Cook NR,Belanger C,LaMotte F,Gaziano JM,Ridker PM,Willett W,Peto R. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996; 334: 11459.
  • 34
    Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 1989; 321: 12935.
  • 35
    Gann PH,Hennekens CH,Ma J,Longcope C,Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996; 88: 111826.